Evaluation of intravenous pamidronate & oral alendronate on bone marrow density in ?patients with major and intermedia thalassemia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017070420258N51

Enrollment

Registered

2017-07-16

Start date

2017-02-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major and inter media thalassemia. Beta thalassaemia

Interventions

Intervention 1: Intervention group: We prescribe 70 milligram Alendronate once a week in A group. Intervention 2: Intervention group: We prescribe 0.5 milligram in kilogram of Pamidronate IV in day f

Treatment - Drugs

Intervention group: We prescribe 70 milligram Alendronate once a week in A group.

Intervention group: We prescribe 0.5 milligram in kilogram of Pamidronate IV in day for three day in B group.

Eligibility

Sex/Gender

All

Age

10 Years to 139 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with major and inter media thalassemia ,age more than 10 years referred to Amir kabir hospital Exclusion criteria: Gastrointestinal intolerance for oral medication; having an allergic drug; heart failure; liver failure; hypoparathyroidism

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Spinal bone density and femoral neck. Timepoint: End of one years. Method of measurement: X-ray photography.;Improve the status of clinical symptoms. Timepoint: End of one years. Method of measurement: clinical observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Aziz Eghbali

Arak University of Medical Sciences

mahmoud.nahremiany@gmail.com+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026